Is it worth to increase the daily dose of telmisartan to 80 mg per day for cardiovascular high-risk patients, who reach blood pressure target on a low dose? Review article
Article Sidebar
Published:
Jun 30, 2016
Keywords:
antihypertensive treatment, cardiovascular high-risk patients, ARB, telmisartan
Main Article Content
Abstract
Efficacy of telmisartan was confirmed in cardiovascular (CV) prevention of high-risk patients (ONTARGET trial). Telmisartan is usually used in a daily dose of 40–80 mg for hypertension treatment, but in order to reduce CV risk a daily dose of 80 mg should be applied.
Article Details
How to Cite
Chmielewski , M., & Kuch , M. (2016). Is it worth to increase the daily dose of telmisartan to 80 mg per day for cardiovascular high-risk patients, who reach blood pressure target on a low dose?. Medycyna Faktow (J EBM), 9(2(31), 94-95. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2240
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego 2015; 1(1): 1-70.
2. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
3. Yusuf S., Teo K.K., Pogue J. et al.; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
2. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342(3): 145-153.
3. Yusuf S., Teo K.K., Pogue J. et al.; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.